Skip to main content
Partnering With Patients Through Advocacy With Allison Rosen, MS
Nate Bargo
Expert Analysis
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares the story of her cancer journey, how she became involved in patient advocacy, and how to strives to use her platform to bridge the gap between clinical research and cancer patients and survivors.  
Trailblazing the Oncology and Palliative Care Fellowship Experience and Finding Your Niche: Richa Thakur, MD, and Nida Khan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · The Value of Integrated Palliative Care Training During Fellowship With Richa Thakur, MD In this Oncology Data Advisor® Fellows Forum interview, Richa Thakur, MD, Hematology/Oncology Fellow at Northwell Health, speaks with Nida Khan, MD, a third-year Internal Medicine Resident who is beginning a joint Medical Oncology and Palliative Care Fellowship this July. Dr. Khan discusses the unique opportunities provided by this new type of fellowship, her passions for palliative care and global health, and advice for navigating the fellowship application process to find your niche in the program that is the best fit for you.  
Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Shubham Pant, Associate Professor in the Department of Medical Oncology at MD Anderson Cancer Center, presented the results of HERIZON-BTC-01, a phase 2b trial investigating zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)–amplified biliary tract cancers. Afterwards he spoke with Oncology Data Advisor to share more about the efficacy, safety, and future directions for zanidatamab. 
Trastuzumab Deruxtecan Safety in HER2-Expressing Solid Tumors With Funda Meric-Bernstam, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Trastuzumab Deruxtecan Safety on HER2 Expressing Solid Tumors With Funda Meric-Bernstam, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Funda Meric-Bernstam, the Department Chair in the Department of Vascular Cancer Therapeutics at MD Anderson Cancer Center, sat down with O...
Hematology/Oncology Trainee Experiences During the COVID-19 Pandemic and Beyond With Samuel Kareff, MD, MPH, and Ana Velazquez Mañana, MD
Keira Smith
Expert Analysis
This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.  
Exciting New Directions for Oncology Data Advisor: Live From ASCO 2023 With Dr. Thomas Abrams, Editor in Chief
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exciting New Directions for Oncology Data Advisor: Live From ASCO 2023 With Dr.Thomas Abrams At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Thomas Abrams, Editor in Chief of Oncology Data Advisor, previewed some of the latest updates on Oncology Data Advisor and the new di...
Exciting New Directions for Oncology Data Advisor: Live From ASCO 2023 With Dr. Thomas Abrams, Editor in Chief
Keira Smith
Expert Analysis
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Thomas Abrams, Editor in Chief of Oncology Data Advisor, previewed some of the latest updates on Oncology Data Advisor and the new directions that will be taken in 2023, including new ways of partnering with patients to strengthen the patient voice and ultimately improve quality of care.  
Understanding and Improving Quality of Life for Cancer Patients Through Nursing Research With Terri Armstrong, PhD, ANP-BC
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Understanding and Improving Quality of Life for Cancer Patients Through Nursing Research Following the recent 48th Oncology Nursing Society (ONS), Terri Armstrong, the Senior Investigator and Deputy Chief of the Neuro-Oncology Branch at the National Institutes of Health (NIH), sat down with Oncology Data Advisor®...
Oncology Data Advisor® Releases Exclusive Video and Podcast Interviews From the 2023 ASCO Annual Meeting
Keira Smith
Expert Analysis
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® had the privilege of interviewing many distinguished physician, nurse, pharmacist, pathologist, and patient advocate speakers about their work and research. These exclusive video and podcast playlists feature more than 30 conversations on a range of topics in oncology treatment and patient care, including the following:
Improving Access to Hereditary Cancer Genetic Testing for Black Individuals and Their Families With Darya Kizub, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Developing Telegenetic Cancer Risk Assessment for Black Individuals With Darya Kizub, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Darya Kizub, Hematology-Oncology Fellow at MD Anderson Cancer Center, presented her team's research regarding a novel initiative for recruiting Black individuals to be screened for hereditary cancer genetic testing eligibility. Prior to presenting, she sat down with Oncology Data Advisor to share more about the need to provide cancer genetic testing for Black individuals and the ways that she and her team have partnered with the community to enact this change.  
Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Dr. Yan Leyfman, a physician at Mount Sinai Hospital and Director and Host of MedNews Week. Dr. Leyfman expl...
Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD
Nate Bargo
Expert Analysis
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Dr. Yan Leyfman, a physician at Mount Sinai Hospital and Director and Host of MedNews Week. Dr. Leyfman explains the origin and reach of MedNews Week and how it strives to combat health care information, champion patient advocacy, and expand global health education through its video and social media platforms.  
Navigating the Residency and Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque, MD
Keira Smith
Expert Analysis
In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring o...
Tigerlily Foundation and Empowering Patients Through the Power of One With Maimah Karmo
Keira Smith
Expert Analysis
In 2006, after being diagnosed with breast cancer at the age of 32, Maimah Karmo decided to dedicate herself to empowering women with breast cancer to serve as advocates for themselves, resulting in the creation of Tigerlily Foundation. In this interview, Ms. Karmo shares more of her story and her passion for amplifying the patient's voice, increas...
Renal Cell Carcinoma Research and Shared Decision Making With Bradley McGregor, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Renal Cell Carcinoma Research and Shared Decision Making With Bradley McGregor, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Bradley McGregor, MD, Director of Clinical Research for the Lank Center of Genitourinary Oncology at th...
Exploring the Primary Overall Survival Results of Axicabtagene Ciloleucel in the ZUMA-7 Trial With Jason Westin, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring Primary Overall Survival Results of Axicabtagene Ciloleucel in ZUMA-7: Jason Westin, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lymphoma Clinical Research at MD Anderson Cancer Center, presented the primary overall survival analysis of the phase 3 ZUMA-7 trial investigating axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomas. In this interview, he shares more with Oncology Data Advisor regarding the efficacy, safety, and future directions of this promising agent. 
Developing Training on Medical Cannabis Education for Oncology Fellows With Deepa Rangachari, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Medical Cannabis Educational Training for Oncology Fellows With Deepa Rangacharia, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Dr. Deepa Rangachari, Director of Hematology/Oncology Graduate Medical Education at Beth Israel Deaconess Medical Center, to learn more about her presentation on her team's development of a novel curriculum to train Hematology/Oncology Fellows in the use of medical cannabis for their patients. 
Social Media’s Effect on Informed Decision Making in Cancer Treatment With Nina Morena, MA, and Ari Meguerditchian, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Social Media’s Effect on Informed Decision Making in Cancer Treatment Welcome to Oncology Data Advisor®, a digital resource for the multidisciplinary cancer team. In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill Universit...
Trailblazing the Oncology and Palliative Care Fellowship Experience and Finding Your Niche: Richa Thakur, MD, and Nida Khan, MD
Keira Smith
Expert Analysis
In this Oncology Data Advisor® Fellows Forum interview, Richa Thakur, MD, Hematology/Oncology Fellow at Northwell Health, speaks with Nida Khan, MD, a third-year Internal Medicine Resident who is beginning a joint Medical Oncology and Palliative Care Fellowship this July. Dr. Khan discusses the unique opportunities provided by this new type of fellowship, her passions for palliative care and global health, and advice for navigating the fellowship application process to find your niche in the program that is the best fit for you.  
Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology Data Advisor® spoke with Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Institute and one of the investigators of the EPCORE NHL-1 trial, on which the approval was based, to learn more about the efficacy and safety of epcoritamab and its burgeoning role in the treatment of relapsed/refractory DLBCL.